Clinical trial
A Phase 1, Exploratory, Randomized, Double-Blind, Two-Way Cross Over Study to Assess Pharmacokinetic and Pharmacodynamic Effects of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Subjects With Type 1 Diabetes Mellitus
NCT02506647 is registered in ClinicalTrials.gov with Gan and Lee Pharmaceuticals, USA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Exploratory, Randomized, Double-Blind, Two-Way Cross Over Study to Assess Pharmacokinetic and Pharmacodynamic Effects of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Subjects With Type 1 Diabetes Mellitus
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2015
- Completion date
- September 30, 2016
- Enrollment
- 41 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.